Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists map brain receptors in healthy volunteers using radioactive tracer

NCT ID NCT03520543

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed Phase 1 study involved 16 healthy men aged 20-35 to test a radioactive tracer called [11C]Yohimbine. Researchers used PET scans to see how the tracer binds to certain brain receptors and measured its effects after giving the drug clonidine. The goal was to understand the tracer's behavior in the brain, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[11C]Yohimbine (a radioactive tracer) and clonidine (a drug)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

16 people

The number who actually took part.

Started

May 2018

Finished

Jan 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 35 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male volunteers * Age between 20 years and 35 years * Weight between 50kg and 90kg * Without neurologic or psychiatric history * Without head trauma history including loss of consciousness superior to 30 minutes. * Affiliated to a social security or similar scheme * Not subject to any legal protection measures * Participant must have signed an informed consent document indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study and comply with the study procedures and restrictions Exclusion Criteria: * Allen test (assessing the arterial blood flow to the hand) indicating abnormal blood supply to the hand * Subject with orthostatic hypotension * Subject with alcohol or substance abuses history * Subject with somatic drug therapies * MRI contraindications (implanted or embedded metal objects in the head or body) * PET contraindications * Clonidine contraindications * Exposed to 1 millisievert or more of ionizing radiation in the year before the start of this study * Subject unable to sign written consent for participation in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy controls are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy controls

Contacts and locations

Locations

  • Service de Neurologie C - Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, GHE

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.